Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use OXLUMO® safely and effectively. See full prescribing information for OXLUMO. OXLUMO (lumasiran) injection, for subcutaneous use Initial U.S. Approval: 2020
Medication labelWhy this: Advisory · dailymed-prescription
OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients [see Clinical Pharmacology (12.1), Clinical Studies (14.1, 14.2, 14.3)].
- generic_name
- lumasiran
- product_names
- lumasiran
- ndc
- 71336-1002, 71336-1002-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en